XML 39 R22.htm IDEA: XBRL DOCUMENT
v3.20.4

Segment Reporting | 12 Months Ended
--- | ---
Dec. 31, 2020
Segment Reporting [Abstract] |
Segment Reporting | Segment Reporting The Company operates in three major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities, the operation of ancillary services and the operation of optical services. The Surgical Facility Services segment consists of the operation of ASCs and surgical hospitals and includes anesthesia services. The Ancillary Services segment consists of multi-specialty physician practices and a diagnostic laboratory, which was closed during the third quarter of 2020. The Optical Services segment consists of an optical products group purchasing organization, which was sold on December 31, 2020, as discussed in Note 2. "Acquisitions and Disposals." "All other" primarily consists of the Company's corporate general and administrative functions. The following tables present financial information for each reportable segment (in millions):
|  | Year Ended December 31,
|  | 2020 |  | 2019 |  | 2018
Revenues: |  |  |  |  |  |
Surgical Facility Services |  | $ | 1,793.4 |  |  | $ | 1,748.2 |  |  | $ | 1,682.4 |
Ancillary Services |  | 63.6 |  |  | 79.4 |  |  | 79.6 |
Optical Services |  | 3.1 |  |  | 3.8 |  |  | 9.5 |
Total |  | $ | 1,860.1 |  |  | $ | 1,831.4 |  |  | $ | 1,771.5 |
Adjusted EBITDA: |  |  |  |  |  |
Surgical Facility Services |  | $ | 339.3 |  |  | $ | 328.9 |  |  | $ | 309.5 |
Ancillary Services |  | (3.4) |  |  | 2.6 |  |  | 3.0 |
Optical Services |  | 1.4 |  |  | 1.4 |  |  | 2.5 |
All other |  | (80.7) |  |  | (74.3) |  |  | (80.2) |
Total |  | $ | 256.6 |  |  | $ | 258.6 |  |  | $ | 234.8 |
Reconciliation of Adjusted EBITDA: |  |  |  |  |  |
(Loss) income before income taxes |  | $ | (18.8) |  |  | $ | 54.6 |  |  | $ | (69.2) |
Net income attributable to non-controlling interests |  | (117.4) |  |  | (119.9) |  |  | (110.1) |
Depreciation and amortization |  | 94.8 |  |  | 76.5 |  |  | 67.4 |
Interest expense, net |  | 201.8 |  |  | 178.9 |  |  | 147.0 |
Equity-based compensation expense |  | 13.2 |  |  | 10.2 |  |  | 9.3 |
Transaction, integration and acquisition costs (1) |  | 38.2 |  |  | 36.1 |  |  | 34.0 |
Impairment charges |  | 33.5 |  |  | 7.9 |  |  | 74.4 |
Loss (gain) on disposals and deconsolidations, net |  | 5.7 |  |  | (4.4) |  |  | 31.8 |
Litigation settlement and other litigation costs (2) |  | 6.4 |  |  | 4.6 |  |  | 46.0 |
Reserve adjustments (3) |  | — |  |  | — |  |  | 2.7 |
Contingent acquisition compensation expense |  | — |  |  | — |  |  | 1.5 |
Gain on escrow release (4) |  | (0.8) |  |  | — |  |  | — |
Loss on debt extinguishment |  | — |  |  | 11.7 |  |  | — |
Tax receivable agreement expense |  | — |  |  | 2.4 |  |  | — |
Adjusted EBITDA |  | $ | 256.6 |  |  | $ | 258.6 |  |  | $ | 234.8 |
(1)For the year ended December 31, 2020, this amount includes transaction and integration costs of $23.2 million, of which $6.6 million were acquisition related costs, and includes start-up costs related to a de novo surgical hospital of $15.0 million. For the year ended December 31, 2019, this amount includes transaction and integration costs of $19.0 million, and includes other acquisition costs and start-up costs related to a de novo surgical hospital of $17.1 million. For the year ended December 31, 2018, this amount includes transaction and integration costs of $31.7 million, and includes other acquisition costs of $2.3 million. (2)This amount includes litigation settlement costs of $1.2 million, $0.2 million and $46.0 million for the years ended December 31, 2020, 2019 and 2018, respectively. This amount further includes other litigation costs of $5.2 million and $4.4 million for the years ended December 31, 2020 and 2019, respectively, with no comparable costs in 2018. (3)This amount represents adjustments to revenue in order to apply consistent policies to businesses acquired by Surgery Partners in prior periods. (4)Included in other income in the consolidated statement of operations for the year ended December 31, 2020, with no comparable gain in 2019 and 2018.
|  | December 31,
|  | 2020 |  | 2019
Assets: |  |  |  |
Surgical Facility Services |  | $ | 4,962.4 |  |  | $ | 4,580.4 |
Ancillary Services |  | 35.0 |  |  | 69.6 |
Optical Services |  | — |  |  | 17.7 |
All other |  | 415.8 |  |  | 351.2 |
Total assets |  | $ | 5,413.2 |  |  | $ | 5,018.9 |
|  | Year Ended December 31,
|  | 2020 |  | 2019 |  | 2018
Cash purchases of property and equipment: |  |  |  |  |  |
Surgical Facility Services |  | $ | 38.7 |  |  | $ | 65.9 |  |  | $ | 34.2 |
Ancillary Services |  | 0.4 |  |  | 1.1 |  |  | 0.4 |
All other |  | 3.8 |  |  | 6.6 |  |  | 5.2 |
Total cash purchases of property and equipment |  | $ | 42.9 |  |  | $ | 73.6 |  |  | $ | 39.8 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration